振东制药
(300158)
| 流通市值：51.67亿 | | | 总市值：51.70亿 |
| 流通股本：9.92亿 | | | 总股本：9.92亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,096,512,580.03 | 649,133,317.06 | 2,783,059,374.58 | 2,214,507,098.61 |
| 营业收入 | 1,096,512,580.03 | 649,133,317.06 | 2,783,059,374.58 | 2,214,507,098.61 |
| 二、营业总成本 | 1,174,522,984.88 | 657,931,700.5 | 3,109,138,419 | 2,206,677,387.24 |
| 营业成本 | 514,225,627.3 | 300,384,411.88 | 1,389,945,100.8 | 1,042,476,724.91 |
| 税金及附加 | 13,069,031.36 | 7,112,184.53 | 31,359,898.04 | 23,775,444.1 |
| 销售费用 | 415,503,001.48 | 234,194,836.38 | 1,178,895,313.81 | 822,857,844.03 |
| 管理费用 | 138,675,614.74 | 69,539,981.72 | 327,622,805.01 | 202,244,468.16 |
| 研发费用 | 89,711,342.57 | 45,476,042.33 | 179,898,551.89 | 114,643,536.85 |
| 财务费用 | 3,338,367.43 | 1,224,243.66 | 1,416,749.45 | 679,369.19 |
| 其中:利息费用 | 3,021,411.16 | 1,095,776.7 | 1,064,152.37 | 1,097,983.34 |
| 其中:利息收入 | 73,381.66 | 121,431.77 | 1,315,376.39 | 1,576,791.74 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 251,967.83 | 930,982.68 | 1,586,150.58 | 1,149,900.19 |
| 加:投资收益 | 330,970.02 | -289,888.48 | 10,781,530.12 | 8,890,277.02 |
| 资产处置收益 | - | - | -633,441.94 | 707,922.86 |
| 资产减值损失(新) | -25,569,063.89 | -2,899,606.77 | 658,173.79 | -8,781,229.16 |
| 信用减值损失(新) | -14,818,026.59 | -926,853.03 | -6,255,473.34 | -1,674,305.63 |
| 其他收益 | 23,904,600.42 | 15,932,165.14 | 55,004,311.03 | 45,888,483.67 |
| 四、营业利润 | -93,909,957.06 | 3,948,416.1 | -264,937,794.18 | 54,010,760.32 |
| 加:营业外收入 | 189,502.5 | 260,246.5 | 1,110,450.28 | 1,206,086.03 |
| 减:营业外支出 | 3,419,975.58 | 1,259,251.59 | 13,795,354.51 | 9,475,536.97 |
| 五、利润总额 | -97,140,430.14 | 2,949,411.01 | -277,622,698.41 | 45,741,309.38 |
| 减:所得税费用 | -1,838,467.52 | 4,138,097.91 | 25,463,924.78 | 27,365,566.38 |
| 六、净利润 | -95,301,962.62 | -1,188,686.9 | -303,086,623.19 | 18,375,743 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -95,301,962.62 | -1,188,686.9 | -303,086,623.19 | 18,375,743 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -92,725,464.95 | -1,045,910.55 | -301,061,698.8 | 20,364,069.93 |
| 少数股东损益 | -2,576,497.67 | -142,776.35 | -2,024,924.39 | -1,988,326.93 |
| 扣除非经常损益后的净利润 | -107,483,410.29 | -11,112,399.12 | -323,316,732.68 | 507,544.83 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.09 | 0 | -0.3 | 0.02 |
| (二)稀释每股收益 | -0.09 | 0 | -0.3 | 0.02 |
| 八、其他综合收益 | 130,132.49 | -2,794.77 | 1,101,205.69 | -736,346.78 |
| 归属于母公司股东的其他综合收益 | 130,132.49 | -2,794.77 | 1,101,205.69 | -736,346.78 |
| 九、综合收益总额 | -95,171,830.13 | -1,191,481.67 | -301,985,417.5 | 17,639,396.22 |
| 归属于母公司股东的综合收益总额 | -92,595,332.46 | -1,048,705.32 | -299,960,493.11 | 19,627,723.15 |
| 归属于少数股东的综合收益总额 | -2,576,497.67 | -142,776.35 | -2,024,924.39 | -1,988,326.93 |
| 公告日期 | 2026-08-26 | 2026-04-21 | 2026-04-21 | 2025-10-23 |
| 审计意见(境内) | | | 标准无保留意见 | |